1453208-09-7

Basic information

• Product Name: 5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine
• Synonyms: 5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine
• CAS NO: 1453208-09-7
• Molecular Weight: 584.666
• Mol File: 1453208-09-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine(1453208-09-7)
• EPA Substance Registry System: 5-[(2,6-difluoro-3,5-dimethoxybenzyl)oxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine(1453208-09-7)

Safety Data

• Hazardous Substances Data: 1453208-09-7(Hazardous Substances Data)

Upstream product

• 1254058-34-8 3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]aniline 
• 1453211-61-4 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine 
• 651734-55-3 methyl 2,6-difluoro-3,5-dimethoxybenzoate 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION HAVING PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT

[Problem] A pharmaceutical composition for treating FGFR4-related cancer, FGF 19-related cancer, or FGF19 gene amplification-positive liver cancer is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory ac

NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND

Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.